Last Updated on April 26, 2022 by Team Spinfuel
For the first time, cannabis-based medicines have been approved in the UK to be used on the National Health Service. Also, a huge medical trial of the medical use of cannabis has been scheduled.
Now, you see, the U.K. has been ahead of the curve on vaping and other methods of harm reduction and curative properties of cannabis. (They also have a very relax attitude on nudity and language on TV screens across the U.K., but that’s another topic entirely)
After speaking to our publisher, someone that has long suffered chronic pain diseases, he is of the opinion that the only people to get any benefit from cannabis in any form are those that enjoy being stoned. He does not enjoy it, so any curative properties are of no use to people like our publisher.
From the London Economic
“Two cannabis-based medicines have been recommended for use on the NHS for the first time. Epidyolex has been approved for two rare types of epilepsy, Lennox-Gastaut and Dravet syndromes, while the spray Sativex has been recommended for muscle spasms in multiple sclerosis (MS). Charities welcomed the move but said thousands of other people who could benefit from cannabis-based medicines were left in limbo.”
Okay, treating diseases like epilepsy, Lennox-Gastaut and Dravet syndromes, as well as MS, are definitely worth trying the cannabis-based medicines. Interestingly, the product Sativex does peak our interest. Sativex is a mouth (oromucosal) spray that contains two chemical extracts derived from the cannabis plant: delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD). The number of sprays is gradually increased each day until the optimum dose is reached. It should be noted that Sativex will get the patient somewhat high from the THC it contains, but from what we’ve read, the CBD in Sativex should ease the high a little.
The Report Goes on to Say:
However in other news that could pave the way to the legalization of whole-plant cannabis for medicinal uses, the largest medical trial ever of cannabis in Europe was unveiled at the end of last week. Project Twenty21 could pave the way for millions of Brits to be treated with the plant. Up to 20,000 people will be trialing cannabis for its effects on epilepsy, multiple sclerosis, chronic pain, post-traumatic stress disorder, Tourette’s syndrome, anxiety disorder, and substance abuse.